Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564290 | 0.80 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL1037957 | 0.80 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL1965663 | 0.79 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL967286 | 0.77 | — | — | |
| SCHEMBL423782 | 0.76 | CA2 (0.43) | CA2CA12CA1CA9CHKA | |
| SCHEMBL965723 | 0.75 | ALDH1A1 (0.48) | CA2CHKAHPGDPOLB | |
| SCHEMBL2288243 | 0.73 | CYP1A2 (0.54) | HSD11B1POLBEPHX2 | |
| SCHEMBL5433 | 0.72 | — | — | |
| SCHEMBL603099 | 0.72 | — | — | |
| SCHEMBL967471 | 0.71 | SMN1; SMN2 (0.54) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | claimed |
| CN-101238129-A | Compounds that maintain pluripotency of embryonic stem cells | IRM LLC (BM) | 2008-08-06 | — | — | CN | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| EP-1899344-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM, LLC (BM) | 2008-03-19 | — | — | EP | claimed |
| JP-2007500725-A | — | — | 2007-01-18 | — | — | JP | claimed |
| WO-2006135824-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2006-12-21 | — | — | WO | claimed |
| CN-1860118-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-08 | — | — | CN | claimed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| EP-0530537-B1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-01-08 | — | — | EP | claimed |
| US-5403843-A | Pyrrolopyrimidinyalglutaminate derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-04 | — | — | US | claimed |
| US-5227380-A | Topoisomerase I inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 1993-07-13 | — | — | US | claimed |
| EP-0530537-A1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-10 | — | — | EP | claimed |
| US-5122526-A | Toposomerase inhibitors; antitumor agents | RESEARCH TRIANGLE INSTITUTE (US) | 1992-06-16 | — | — | US | claimed |
| EP-0436653-A4 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | — | 1992-01-15 | — | — | EP | claimed |
| EP-0436653-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1991-07-17 | — | — | EP | claimed |
| US-4981968-A | ENZYME INHIBITORS, ANTITUMOR | RESEARCH TRIANGLE INSTITUTE (US) | 1991-01-01 | — | — | US | claimed |
| WO-1990003169-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1990-04-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | LIFR, ALPG, BMI1 | CA2 4294/4885CA12 1763/4885CA1 1883/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | CA2 2629/4885CA12 4439/4885CA1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.